The Role of Gliclazide on microRNA-150 Expression in Patients with Type 2 Diabetes Mellitus and Left Ventricular Diastolic Dysfunction

Back ground: Left ventricular diastolic dysfunction (LVDD) is a common complication observed in patients with type 2 diabetes mellitus(T2DM) and is associated with increased cardiovascular morbidity and mortality.
MicroRNAs (miRNAs) have emerged as important regulators of gene expression and have been implicated in the pathogenesis of LVDD. This study aimed to investigate the role of gliclazide, an oral antidiabetic medication, on the expression of microRNA-150 (miR-150) in patients with T2DM and LVDD.
Objective: this study was to investigate the effects of the antidiabetic medication gliclazide on the expression of microRNA-150 (miR-150) in individuals with both left ventricular diastolic dystunction (LVDD) and type 2 diabetes mellitus (T2DM).
Method: A total of 62 patients with T2DM and LVDD were enrolled in this study and were randomly assigned to receive either gliclazide treatment or standard care for a period of 6 months . Blood samples were collected from all participants at baseline treatment period. The expression levels of miR-150 were measured using quantitative real-time polymerase chain reaction (qRT-PCR).
Result: the patients with T2DM and LVDD exhibited significantly increased expression of miR-150 compared to healthy controls. However, after 6 months of gliclazide treatment, there was a significant upregulation of miR-150 expression in the treatment group compared to the control group, These findings suggest that gliclazide treatment may have a beneficial effect on LVDD in patients with T2DM by modulating the expression of miR-150. MiR-150 has been implicated in the regulation of cardiac hypertrophy and fibrosis, which are key processes involved in the development of LVDD. Therefore, the upregulation of mir-150 by gliclazide may contribute to the amelioration of LVDD through the attenuation of cardiac remodeling.
Conclusion: The gliclazide treatment in patients with T2DM and LVDD was associated with a increase in miR-150 expression and improvements in diastolic function. These findings highlight the potential of miR-150 as a therapeutic target for the management of LVDD in patients with T2DM and suggest that gliclazide may have additional benefits beyond glycemic control in this patient population. Further research is warranted to elucidate the underlying mechanisms and clinical implications of miR-150 modulation in the context of LVDD and T2DM.